Patents Assigned to GLENMARK
  • Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
    Patent number: 9532988
    Abstract: The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: January 3, 2017
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Srinivas Gullapalli, Praveen Kumar Gupta, Maulik Nitinkumar Gandhi
  • Process for the preparation of teneligliptin
    Patent number: 9518048
    Abstract: A process for the preparation of teneligliptin.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: December 13, 2016
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Suresh Mahadev Kadam, Bipin Parsottam Kansagra, Ramchandran Vishnue Kale, Jayant Prakashrao Patil, Venkataramana Reddy Yemireddy, Shailendra Nilkanth Bhadane, Uddhav Popat Chaudhar, Ulhas Digambar Patil, Shekhar Bhaskar Bhirud
  • Process for the preparation of arformoterol or salt thereof
    Patent number: 9499475
    Abstract: Provided is an improved process for the preparation of arformoterol L-(+)-tartrate, and more specifically provided is a novel process for the preparation of arformoterol L-(+)-tartrate via arformoterol D-(?)-tartrate.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 22, 2016
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Shekhar Bhaskar Bhirud, Suresh Mahadev Kadam, Sachin Baban Gavhane, Shailesh Shrirang Pawase, Aniket Ashokrao Deshpande, Anil Subhash Bhujbal
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 9493563
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: November 15, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Thienopyrimidinedione derivatives as TRPA1 modulators
    Patent number: 9474758
    Abstract: The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: October 25, 2016
    Assignee: GLENMARK PHARMACEUTICALS, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Nayan Taterao Waghmare, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
  • Amides of 2-amino-4-arylthiazole compounds and their salts
    Patent number: 9458173
    Abstract: The present disclosure is directed to salts of N-{4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetamide and process for the preparation thereof (formula II).
    Type: Grant
    Filed: June 8, 2013
    Date of Patent: October 4, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Suresh Mahadev Kadam, Abraham Thomas, Sukumar Sinha, Sukeerthi Kumar, Bipin Parsottam Kansagra, Sachin Gavhane, Sandeep Bandu Khandagale, Shailesh Pawase, Jayant Prakashrao Patil, Shailendra Bhadane, Bhavna Mishra, Rajesh Dwivedi
  • Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds
    Patent number: 9440927
    Abstract: The present invention provides a process for the preparation of substituted 3?-hydrazino-biphenyl-3-carboxylic acid compounds. The present invention further provides a process for the preparation of 3?-{N?-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo -1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2?-hydroxybiphenyl-3-carboxylic acid, its intermediate compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 13, 2016
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Bhargav Krishnaji Upadhye, Shivaji Eknath Jagadale, Mukesh Soni
  • Triazolone compounds as mPGES-1 inhibitors
    Patent number: 9439890
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 13, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
    Patent number: 9370483
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 21, 2016
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Process for the preparation of dipeptidylpeptidase inhibitors
    Patent number: 9353114
    Abstract: Provided is a process for the preparation of linagliptin of Formula I, comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyi, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: May 31, 2016
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Sunil Kumar Singh, Sachin Srivastava, Shekhar Bhaskar Bhirud
  • Antibodies that bind to TL1A and their uses
    Patent number: 9290576
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: March 22, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine Attinger, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
  • PROCESS FOR THE PREPARATION OF RIVAROXABAN
    Publication number: 20160052919
    Abstract: Disclosed is a process for the preparation of rivaroxaban and purifying rivaroxaban.
    Type: Application
    Filed: March 21, 2014
    Publication date: February 25, 2016
    Applicant: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Shrikant Prabhakar Keshav, Sanjay Shashikant BHISE, Hemant Harishchandra KAMBLE, Ganesh CHAUDHARI, Deepak Subhash PATIL, Srinivas Reddy SANIKOMMU, Kumar Hari BHUSHAN, Shekhar Bhaskar BHIRUD
  • Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
    Patent number: 9227958
    Abstract: An amorphous form of aprepitant and a process for its preparation is provided. Also provided are mixtures of polymorph Forms I and II of aprepitant and a process for the preparation thereof.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 5, 2016
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Mangesh Shivram Sawant, Girish Dixit, Nitin Sharad Chandra Pradhan, Mubeen Ahmad Khan, Sukumar Sinha
  • PROCESS FOR THE PREPARATION OF IVACAFTOR AND SOLVATES THEREOF
    Publication number: 20150376134
    Abstract: The present invention provides process for the preparation of ivacaftor and solvates thereof.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 31, 2015
    Applicant: Glenmark Pharmaceuticals Limited
    Inventors: Shekhar Bhaskar BHIRUD, Samir NAIK, Sachin SRIVASTAVA, Ramesh Santosh BADGUJAR, Sachin LAD, Sukumar SINHA, Mohammad Amjed KHAN
  • PROCESS FOR THE PREPARATION AND PURIFICATION OF APIXABAN
    Publication number: 20150353543
    Abstract: The present invention provides a process for the preparation and purification of apixaban.
    Type: Application
    Filed: January 15, 2014
    Publication date: December 10, 2015
    Applicant: Glenmark Pharmaceuticals Limited
    Inventors: Shekhar Bhaskar BHIRUD, Sushanta MISHRA, Suresh Babu Narayanan, Sachin Bhagwan NAYKODI, Samir NAIK, Sachin SRIVASTAVA, Pramod Vitthal PATIL
  • ANTIBODY FORMULATION
    Publication number: 20150343058
    Abstract: A pharmaceutical formulation is described comprising a therapeutically effective amount of an antibody, an acetate buffer, a lyoprotectant, a bulking agent and a surfactant.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 3, 2015
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Jonathan André ALBANESE, Roberto Pier-Lorenzo GIOVANNINI, Kevin Niall O'MAHONY
  • PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF
    Publication number: 20150336961
    Abstract: The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
    Type: Application
    Filed: December 27, 2013
    Publication date: November 26, 2015
    Applicant: Glenmark Pharmaceuticals Limited
    Inventors: Shekhar Bhaskar BHIRUD, Sushanta MISHRA, Suresh Babu Narayanan, Sachin Bhagwan NAYKODI, Abhijit Ajaysinh PARDESHI, Ashu DHIMAN, Samir NAIK
  • Treatment of respiratory disorders using TRPA1 antagonists
    Patent number: 9186360
    Abstract: The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 17, 2015
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Indranil Mukhopadhyay, Vidya Ganapati Kattige, Vikram Mansingh Bhosale, Dinesh Pradeep Wale, Abraham Thomas, Sukeerthi Kumar, Sachin Sundarlal Chaudhari
  • PHARMACEUTICAL COMPOSITION COMPRISING BENDAMUSTINE
    Publication number: 20150297523
    Abstract: The present invention relates to a pre-lyophilized composition comprising bendamustine or its pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, an organic solvent and water. Furthermore, the present invention provides a stable pharmaceutical composition comprising bendamustine hydrochloride prepared from such pre-lyophilized composition, a process for preparing such composition; and its use in the treatment of cancer.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 22, 2015
    Applicant: Glenmark Pharmaceuticals Limited
    Inventors: Ulhas Dhuppad, Dattatray Patil
  • PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20150239991
    Abstract: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
    Type: Application
    Filed: September 25, 2013
    Publication date: August 27, 2015
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Fabrizio Comper, Romain Ollier, Paul Wassmann